Host: |
HEK293 cells |
Reactivity: |
Human |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human IL-13RA1/CD213a1-C-hFc&His protein was developed from hek293 cells and has a target region of C-hFc&His. For use in research applications. |
Formulation: |
Lyophilized from a 0.22 Mu m filtered solution of PBS, pH 7.4. Contact us for customized product form or formulation. |
Gene Symbol: |
IL13RA1 |
Gene ID: |
3597 |
Uniprot ID: |
I13R1_HUMAN |
Immunogen: |
Recombinant Human IL-13RA1/CD213a1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Met 1-Thr 343) of human IL13RA1 (Accession #NP_001551.1) fused with an Fc, 6×His tag at the C-terminus. |
Tissue Specificity | Ubiquitous. Highest levels in heart, liver, skeletal muscle and ovary.lowest levels in brain, lung and kidney. Also found in B-cells, T-cells and endothelial cells. |
Function | Binds with low affinity to interleukin-13 (IL13). Together with IL4RA can form a functional receptor for IL13. Also serves as an alternate accessory protein to the common cytokine receptor gamma chain for interleukin-4 (IL4) signaling, but cannot replace the function of IL2RG in allowing enhanced interleukin-2 (IL2) binding activity. |
Protein Name | Interleukin-13 Receptor Subunit Alpha-1Il-13 Receptor Subunit Alpha-1Il-13r Subunit Alpha-1Il-13r-Alpha-1Il-13ra1Cancer/Testis Antigen 19Ct19Cd Antigen Cd213a1 |
Database Links | Reactome: R-HSA-6785807 |
Cellular Localisation | MembraneSingle-Pass Type I Membrane Protein |
Alternative Protein Names | Interleukin-13 Receptor Subunit Alpha-1 proteinIl-13 Receptor Subunit Alpha-1 proteinIl-13r Subunit Alpha-1 proteinIl-13r-Alpha-1 proteinIl-13ra1 proteinCancer/Testis Antigen 19 proteinCt19 proteinCd Antigen Cd213a1 proteinIL13RA1 proteinIL13R proteinIL13RA protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance